Basecamp Research, a frontier artificial intelligence company focused on AI-designed medicines, announced a $140 million Series C financing round on Wednesday. The oversubscribed round values the London-based company at $800 million and was led by S32 with participation from NVIDIA and Anthropic's Anthology Fund, among others. The new capital will support the development of its EDEN biological foundation models and move a pipeline of AI-designed therapies toward clinical testing.
Funding Details and Strategic Backers
The Series C attracted a broad group of investors from technology, health care and global institutions. In addition to lead investor S32, participants included Catalio Capital Management, the NATO Innovation Fund, the Rockefeller Foundation, Singular, True Ventures and Redalpine. Basecamp Research previously raised $60 million in a Series B round in October 2024, which was led by Singular.
Advancing EDEN-Designed Therapeutics
Basecamp Research plans to use the financing to train a new generation of its EDEN biological foundation models and advance therapeutic candidates toward clinical development. The company will initially focus on in vivo cell therapy, an approach that reprograms a patient's cells inside the body instead of requiring external manufacturing. This strategy could make cell therapies more customizable and easier to administer for cancer and autoimmune diseases.
A New Approach to Cell Therapy
The company said current cell therapies can cost hundreds of thousands of dollars per patient and remain constrained by complex manufacturing. By pairing EDEN's ability to design long and complex DNA sequences with large serine recombinases, Basecamp aims to improve precision and accessibility. The company has reported strong preclinical results across multiple disease areas, though it has not provided a timeline for clinical trials.
Proprietary Data and Technology Foundation
EDEN is trained on Basecamp Research's proprietary genomic dataset, known as the Trillion Gene Atlas, which the company describes as the world's largest proprietary biological AI training dataset. The dataset was built through access and benefit-sharing partnerships in more than 30 countries across all seven continents, with support from partners including NVIDIA, Anthropic, PacBio and Ultima Genomics. Unlike single-task AI systems, EDEN models are designed to provide a universal understanding of how DNA works across all life.
Leadership and Commercial Expansion
Basecamp Research also announced the appointment of Richard Pearce, formerly of Biogen, as chief business officer to expand pharmaceutical partnerships. Andy Conrad, general partner at S32 and former CEO of Verily, will join the company's board of directors. Conrad said the ability to combine AI, biological data and scientific insight could transform how medicines are discovered and ultimately improve lives.
Executive Perspective
Glen Gowers, co-founder and chief executive officer of Basecamp Research, said the company believes the future of medicine lies in reprogramming the body to repair itself. He added that AI-based approaches promise to change what is possible for patients who currently have few alternatives. The funding brings this technology closer to patients who need it most, according to the company.
The Series C round reinforces investor confidence in Basecamp Research's ambition to develop cures for diseases that remain incurable by combining frontier AI with proprietary biological data. With new capital, strengthened leadership and a growing network of scientific and commercial partners, the company is positioned to advance its EDEN platform toward clinical applications. Its progress will be closely watched as the biotechnology and artificial intelligence sectors continue to converge.